AbCellera Biologics Inc. (ABCL): A Bull Case Theory [Yahoo! Finance]
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Yahoo! Finance
AbCellera Biologics Inc.'s share was trading at $3.6200 as of January 21st. ABCL's trailing P/E was 19.92 according to Yahoo Finance. Pixabay/Public Domain AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. ABCL is transitioning into a critical maturity phase as it evolves from a service-oriented antibody discovery platform into a clinical-stage biotech with proprietary drug candidates. Historically known for its AI-powered discovery engine and its rapid COVID-19 antibody work with Eli Lilly, AbCellera spent 2024 and 2025 deliberately pivoting toward internal and co-developed programs that can generate outsized long-term value. While the stock has collapsed more than 90% from its post-IPO highs and now trades near $4.50, this prolonged bottoming phase reflects skepticism about whether the platform can consistently translate discovery into drugs rather than a deterioration of the un
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- Short sales on the TSX: Where are the sellers as software stocks tumble? [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Reassessing AbCellera Biologics (ABCL) After A Sharp 16.8% Weekly Share Price Drop [Yahoo! Finance]Yahoo! Finance
- AbCellera to Report Full Year 2025 Financial Results on February 24, 2026Business Wire
- AbCellera Biologics (NASDAQ:ABCL) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ABCL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 [Yahoo! Finance]Yahoo! Finance
ABCL
Earnings
- 11/6/25 - Miss
ABCL
Sec Filings
- 1/14/26 - Form 8-K
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- ABCL's page on the SEC website